RE:US$10 Billion is a typical estimate for a M&A in 2023Inflation is a driver for Big Pharma companies like Pfizer, with large cash reserves, to put that cash to work in the form of M&A activites - given the fact that inflation is eroding the purchasing power of Big Pharma's cash reserves and has the effect of increasing the cost of debt financing.
Furthermore Big Pharma's patent cliff is another driver that will have global pharma companies acquiring innovative companies like ONCY with "bolt-on" assets that address unmet clinical treatment needs in the range of US$10 Billion.